Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and ...

Feb 26 () - Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss ‌pill, ...

A West Michigan man has been accused of selling misbranded weight loss drugs to U.S. consumers without a valid prescription.

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but ...

NVO shares plunge 21% after Lilly's Zepbound and oral orforglipron beat its key GLP-1 drugs in head-to-head obesity and ...

A SAYS investigation found some medical practitioners are selling prescription weight-loss drugs like Ozempic without proper ...

Lilly’s new data show its oral GLP-1 beating Novo’s on major benchmarks.

Novo Nordisk announced plans to drastically reduce the list price of its versions, Wegovy, Ozempic and Rybelsus.

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

Novo Nordisk reported a loss in a head-to-head trial of CagriSema against Lilly’s Zepbound earlier this week. This time around, Lilly's orforglipron bested Novo's oral semaglutide in blood sugar ...